Table 2 Baseline demographics and clinical characteristics: patients with ILD history using the most sensitive ILD definition
New anti-TNF Treatment episodes | New tocilizumab Treatment episodes | New rituximab Treatment episodes | New abatacept Treatment episodes | |
|---|---|---|---|---|
N = 232 | N = 59 | N = 99 | N = 109 | |
Female, n (%)a | 172 (74.1) | 47 (79.7) | 75 (75.8) | 82 (75.2) |
Age, mean (SD)a | 60.4 (11.9) | 59.4 (12.3) | 62.1 (11.0) | 61.2 (10.3) |
Geographic region, n (%)a | ||||
Northeast | 36 (15.5) | 9 (15.3) | 13 (13.1) | 15 (13.8) |
North Central | 73 (31.5) | 16 (27.1) | 42 (42.4) | 35 (32.1) |
South | 78 (33.6) | 26 (44.1) | 24 (24.2) | 43 (39.4) |
West | 43 (18.5) | 8 (13.6) | 20 (20.2) | 15 (13.8) |
Rural indicator, n (%)a | 32 (13.8) | 6 (10.2) | 18 (18.2) | 20 (18.3) |
Medicare primary payer, n (%)a | 78 (33.6) | 17 (28.8) | 43 (43.4) | 35 (32.1) |
Follow-up person years per patient, mean (SD) | 0.7 (0.5) | 0.6 (0.5) | 0.7 (0.5) | 0.7 (0.6) |
No of prior biologics, mean (SD)b,c | 1.6 (0.9) | 2.3 (1.2) | 1.7 (0.9) | 1.6 (0.9) |
Prior exposure to ≥2 biologics | 45 (19.4) | 30 (50.8) | 27 (27.3) | 10 (9.2) |
Prior exposure to ≥3 biologics | 12 (5.2) | 6 (10.2) | 2 (2.0 | 0 (0.0) |
RA medication history, n (%)d | ||||
Any anti-TNFα agentb | 135 (58.2) | 21 (35.6) | 42 (42.4) | 69 (63.3) |
Methotrexate | 73 (31.5) | 25 (42.4) | 39 (39.4) | 44 (40.4) |
All other DMARDs | 108 (46.6) | 21 (35.6) | 52 (52.5) | 54 (49.5) |
Prescription NSAIDs | 98 (42.2) | 22 (37.3) | 31 (31.3) | 37 (33.9) |
Glucocorticoid daily dosage, mean (SD)e | ||||
Noneb | 40 (17.2) | 7 (11.9) | 9 (9.1) | 21 (19.3) |
<7.5 mg/day | 124 (53.4) | 28 (47.5) | 44 (44.4) | 57 (52.3) |
≥7.5 mg/day | 68 (29.3) | 24 (40.7) | 46 (46.5) | 31 (28.4) |
Comorbid condition, n (%)f | ||||
Anemiab | 4 (1.7) | 3 (5.1) | 3 (3.0) | 3 (2.8) |
Asthma | 23 (9.9) | 5 (8.5) | 12 (12.1) | 5 (4.6) |
Cerebrovascular disease | 7 (3.0) | 2 (3.4) | 4 (4.0) | 4 (3.7) |
COPDb | 41 (17.7) | 13 (22.0) | 27 (27.3) | 18 (16.5) |
Diabetes | 41 (17.7) | 16 (27.1) | 20 (20.2) | 25 (22.9) |
Heart failure | 12 (5.2) | 5 (8.5) | 8 (8.1) | 12 (11.0) |
Hypertension | 72 (31.0) | 20 (33.9) | 34 (34.3) | 36 (33.0) |
Ischemic heart diseaseb | 23 (9.9) | 2 (3.4) | 10 (10.1) | 21 (19.3) |
Pneumonia | 35 (15.1) | 15 (25.4) | 24 (24.2) | 17 (15.6) |
Any pulmonary condition other than ILDb | 81 (34.9) | 26 (44.1) | 50 (50.5) | 32 (29.4) |
Scleroderma | 3 (1.3) | 0 (0.0) | 4 (4.0) | 6 (5.5) |
Sjögren’s | 5 (2.2) | 2 (3.4) | 4 (4.0) | 1 (0.9) |
SLE | 4 (1.7) | 2 (3.4) | 3 (3.0) | 3 (2.8) |
Any oxygen use, n (%)f | 39 (16.8) | 11 (18.6) | 26 (26.3) | 18 (16.5) |
Hospitalization, n (%)g | ||||
ILD | 18 (7.8) | 9 (15.3) | 21 (21.2) | 13 (11.9) |
Pneumonia | 24 (10.3) | 8 (13.6) | 18 (18.2) | 12 (11.0) |
Asthma | 5 (2.2) | 1 (1.7) | 5 (5.1) | 1 (0.9) |
COPD | 20 (8.6) | 1 (1.7) | 14 (14.1) | 7 (6.4) |
Deyo-adapted CCI, mean (SD)f | 2.2 (1.4) | 2.1 (1.0) | 2.4 (1.4) | 2.4 (1.6) |